While decitabine has proven effective for treating myelodysplastic syndromes, the novel DNMT1 inhibitor guadecitabine shows promise in targeting solid tumors and addressing some of the limitations faced by earlier inhibitors. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.